Business Wire

HCHF

15.5.2020 20:50:06 CEST | Business Wire | Press release

Share
Millions Across the Globe Unite in Prayer for End of Coronavirus Pandemic in Response to HCHF Call

The world has witnessed what is described as an unprecedented historic scene on Thursday, 14th May, when millions of people around the world united in prayer to supplicate to God for an end to the COVID-19 pandemic and to help scientists and researchers find a vaccine against the disease as quickly as possible.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200515005533/en/

This came in response to the Higher Committee of Human Fraternity (HCHF) humanitarian call, which was blessed and supported by His Eminence Dr. Ahmed El-Tayeb, Grand Imam of Al Azhar, and His Holiness Pope Francis, Head of the Catholic Church, and received the support of a number of kings, presidents, leaders, and leading political, religious, and media figures from all over the world.

The HCHF’s call to pray for humanity, which was announced in a statement issued in 14 languages, gained momentum on social media platforms, as the initiative recorded 36 billion cumulative digital media interactions, engagement and potential reach as estimated by Talkwalker analytics report, since it was launched on 2nd May till 15th May. The initiative’s official website (pray.forhumanfraternity.org) and social media accounts have hosted a 24-hour livestream for the global prayers.

#PrayForHumanity hashtag trended on social media in many countries, including France, Germany, India, KSA, UAE, Spain, Egypt, and Italy, reflecting the great success of the initiative which also attracted the attention of global media.

The HCHF extended thanks to all leaders, religious, political, and popular institutions, and all those who participated in the global prayer day.

Judge Mohamed Abdel Salam, HCHF Secretary-General, praised the unexpected successes of the initiative, stressing that such successes will contribute to achieving a true global unity.

He said: “The voices of supplications to God that were made in an unprecedented humanitarian scene in all continents of the world to end this pandemic are reasons for us to feel optimistic and give us confidence that our unity will help the world overcome this crisis.”

Monsignor Yoannis Lahzi Gaid, Personal Secretary to His Holiness Pope Francis, stated that the participation of different religions and beliefs in this initiative also the global response paves a way forward to continue working for humanity, especially in facing this pandemic. He said: “We will keep supplicating to God and work with our brothers from different religions and beliefs to transform this suffering to an opportunity for more solidarity and fraternity.”

The HCHF is an independent international committee that includes a group of experts and leaders in inter-culture communication and interfaith dialogue. It aims to achieve the higher goals for human fraternity signed by His Eminence Dr. Ahmed El-Tayeb, Grand Imam of Al Azhar, and His Holiness Pope Francis, Head of the Catholic Church, in Abu Dhabi in February 2019, under the patronage of HH Sheikh Mohammed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi, the patron of the Document on Human Fraternity.

*Source: AETOSWire

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release

SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye